Entrada Therapeutics

About

Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.

Boston,Massachusetts,United States
51 - 100
https://www.entradatx.com

Highlights

Details

Last Funding Type: Series Unknown
Last Funding Money Raised: $26M
Industries: Biotechnology,Emergency Medicine,Genetics,Health Care,Medical
Founded date: Jan 1, 2016
Number Of Employee: 51 - 100
Operating Status: Active
Stock Symbol: nasdaq:TRDA
Legal Name: Entrada Therapeutics, Inc.
Also Known As: Entrada

Entrada Therapeutics’ mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada’s technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes. The Company's novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the delivery of molecules into the cytosol. For more information, please visit www.entradatx.com.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

5

$383.09M

Entrada Therapeutics has raised a total of $383.09M in funding over 2 rounds. Their latest funding was raised on Dec 8, 2022 from a Series Unknown round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 8, 2022	Series Unknown	$26M	—	—	—	Detail
Oct 29, 2021	IPO	$181.50M	—	—	—	Detail
Mar 31, 2021	Series B	$116M	14	Wellington Management	—	Detail
Dec 18, 2018	Series A	$59M	5	5AM Ventures MPM Capital	—	Detail
Oct 27, 2016	Seed	$599.99K	—	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

3

14

Entrada Therapeutics is funded by 14 investors. Wellington Management and 5AM Ventures are the most recent investors.

Investor Name	Lead Investor	Funding Round
Wellington Management	Yes	Series B
5AM Ventures	—	Series B
Agent Capital	—	Series B
CureDuchenne Ventures	—	Series B
Goldman Sachs	—	Series B
Greenspring Associates	—	Series B
Moore Strategic Ventures	—	Series B
MPM Capital	—	Series B
MRL Ventures Fund	—	Series B
Point72 Ventures	—	Series B